The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Regulatory News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of general meeting

9 Feb 2015 10:17

RNS Number : 3518E
4d Pharma PLC
09 February 2015
 

4D pharma plc

(the 'Company' or '4D')

Result of general meeting

 

4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, announces that at the General Meeting held earlier today, all the resolutions put to shareholders were duly passed.

 

As a result, the placing announced on 21 January 2015 of 8,475,610 new ordinary shares at 410p per ordinary share to raise £34.75m, is conditional only on Admission which is expected to take place on 10 February 2015.

 

Following Admission, the Company's issued share capital will consist of 60,567,729 ordinary shares. There are no ordinary shares held in treasury. Therefore, in accordance with the FCA's Disclosure and Transparency Rule 5.6.1, the Company confirms that following Admission, the total number of voting rights in the Company will be 60,567,729.

 

For further information please contact:

4D

+ 44 (0) 161 837 6205

Duncan Peyton, Chief Executive Officer

 

Zeus Capital Limited - Nomad and Broker

Ross Andrews/Dan Bate

+44 (0) 161 831 1512

Dominic Wilson

+44 (0) 20 7533 7727

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUGUQCPUPAGGR
Date   Source Headline
21st Dec 20187:00 amRNSDirector/PDMR Shareholding
19th Dec 20187:00 amRNSDirector/PDMR Shareholding
13th Dec 20187:00 amRNSPDMR Dealings
12th Dec 20184:40 pmRNSSecond Price Monitoring Extn
12th Dec 20184:35 pmRNSPrice Monitoring Extension
12th Dec 20187:00 amRNSTrading Statement
8th Nov 20187:00 amRNSClinical Update - Blautix Phase II study
8th Nov 20187:00 amGNW4D pharma plc Announces Clinical Update for Blautix Phase II Study
28th Sep 20187:00 amRNSInterim results
24th Sep 20187:00 amRNSClinical update and publication of studies
14th Aug 20187:00 amRNS4D asthma publication
30th Jul 20187:00 amRNSPublication - microbiota as HDAC inhibitors
27th Jun 20187:00 amRNS4D Presents at IHMC 2018
25th Jun 20184:40 pmRNSSecond Price Monitoring Extn
25th Jun 20184:35 pmRNSPrice Monitoring Extension
13th Jun 20187:00 amRNSMHRA and HPRA clear Blautix Phase II study
12th Jun 20184:51 pmRNSHolding(s) in Company
7th Jun 20187:00 amRNSClinical Collaboration Agreement
4th Jun 20187:00 amRNS4D Presents Phase Ib Clinical Data on Blautix
21st May 201812:08 pmRNSResult of AGM
21st May 20187:00 amRNSMRx0518 - Monotherapy trial approved
8th May 20187:00 amRNSClinical Update - Blautix IND
26th Apr 20187:00 amRNSAnnual Report and Notice of AGM
23rd Apr 20187:00 amRNSFinal Results
21st Mar 20187:00 amRNSOncology candidate update
20th Feb 20187:00 amRNSAppointment of Joint Broker
28th Sep 20177:00 amRNSInterim results
5th Sep 201712:54 pmRNSHolding(s) in Company
24th Aug 20177:00 amRNSIssue of Equity
26th May 20171:59 pmRNSResult of AGM
17th May 20174:40 pmRNSSecond Price Monitoring Extn
17th May 20174:35 pmRNSPrice Monitoring Extension
3rd May 20177:00 amRNSAnnual Report and Notice of AGM
27th Apr 20177:00 amRNSFinal Results
18th Apr 20177:59 amRNSAppointment of Joint Broker
10th Mar 20174:37 pmRNSHolding(s) in Company
6th Mar 20177:00 amRNSClinical Update
13th Dec 20167:00 amRNSClinical Update
9th Nov 20164:40 pmRNSSecond Price Monitoring Extn
9th Nov 20164:35 pmRNSPrice Monitoring Extension
8th Nov 20164:40 pmRNSSecond Price Monitoring Extn
8th Nov 20164:35 pmRNSPrice Monitoring Extension
19th Oct 20164:40 pmRNSSecond Price Monitoring Extn
19th Oct 20164:35 pmRNSPrice Monitoring Extension
30th Sep 20167:00 amRNSInterim results for the period ended 30 June 2016
27th Sep 201610:59 amRNSHolding(s) in Company
15th Sep 20164:40 pmRNSSecond Price Monitoring Extn
15th Sep 20164:35 pmRNSPrice Monitoring Extension
9th Sep 201611:58 amRNSHolding(s) in Company
22nd Aug 20167:00 amRNSClinical Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.